Triple rAAV9 Vector Combinations Encoding Broadly Neutralizing Antibodies Effectively Suppress HIV-1 Infection in Humanized Mice
This study investigated the protective efficacy of two distinct combinations of three recombinant adeno-associated virus serotype 9 (rAAV9) vectors encoding broadly neutralizing antibodies against HIV-1-CombiMab-1 and CombiMab-2-in mice humanized with primary CD4<sup>+</sup> T-lymphocytes. We demonstrated that mice preventively treated with CombiMab-1 or CombiMab-2 did not develop viremia and maintained human CD4+ T-lymphocyte counts following viral challenge, in contrast to control animals. These results demonstrate the significant protective capacity of CombiMab-1 and CombiMab-2 against HIV-1 challenge.
Authors
- Ф. А. Урусов (ORCID: https://orcid.org/0000-0003-2304-7787)
- German Alexandrovich Shipulin (ORCID: https://orcid.org/0000-0002-3668-6601)
- Д. В. Глазкова (ORCID: https://orcid.org/0000-0001-6083-4478)
- D. S. Leontyev (ORCID: https://orcid.org/0000-0001-7761-9870)
- S. M. Yudin (ORCID: https://orcid.org/0000-0002-7942-8004)
- E. V. Bogoslovskaya (ORCID: https://orcid.org/0000-0003-3250-6498)
- Г. М. Цыганова (ORCID: https://orcid.org/0009-0002-1527-949X)
- B. V. Belugin (ORCID: https://orcid.org/0000-0003-2646-9774)
- Anastasia A. Mitiushina
Institutions
- Federal Medical-Biological Agency (RU)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2025-11-15
- DOI
- https://doi.org/10.3390/ijms262211051
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00